The biopharma sector is heading into the final quarter with plenty of work to do to salvage some respectability from what has so far proved to be a turbulent and challenging year. With one more trading day before the books close on the third quarter, we took a quick look at where the industry stands prior to our deeper analysis on its business and financial performance in next week's issue.